Lsalt Peptide

Summary

Lsalt Peptide (CHEMBL5314991) is a phase-3 clinical-stage protein; indicated across 1 condition including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314991
Name	Lsalt Peptide
Type	Protein
Max phase	3

Also known as: Lsalt peptide, Metablok, LSALT PEPTIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04330690	PHASE3	UNKNOWN	Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial
NCT05879432	PHASE2	RECRUITING	LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
NCT04402957	PHASE2	COMPLETED	LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
NCT03772678	EARLY_PHASE1	COMPLETED	A Phase I Study to Evaluate LSALT Peptide

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).